Issue Date: December 12, 2011
Vanderbilt, Janssen Target Schizophrenia
Schizophrenia drug candidates generated from a two-year-old collaboration between the Vanderbilt Center for Neuroscience Drug Discovery and Janssen Pharmaceuticals will soon be ready for Phase I clinical trials. The candidates use allosteric modulators to adjust the activity of neurotransmitter receptors in the brain. “These drug candidates could lead to a fundamentally new approach to treating schizophrenia,” says P. Jeffrey Conn, codirector of the Vanderbilt center, which has been among the most aggressive . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society